OnKure Therapeutics Statistics
Want to see OKUR full AI Analyst Report?
OnKure Therapeutics (OKUR) Stock Statistics & Valuation Metrics
Total Valuation
OnKure Therapeutics has a market cap or net worth of $116.04M. The enterprise value is -$26.46M.
- Market Cap
- $116.04M
- Enterprise Value
- -$26.46M
Share Statistics
OnKure Therapeutics has 40,503,094 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 40,503,094
- Owned by Insiders
- 1.73%
- Owned by Institutions
- 13.57%
Financial Efficiency
OnKure Therapeutics’s return on equity (ROE) is -1.06 and return on invested capital (ROIC) is -110.93%.
- Return on Equity (ROE)
- -1.06
- Return on Assets (ROA)
- -0.96
- Return on Invested Capital (ROIC)
- -110.93%
- Return on Capital Employed (ROCE)
- -1.12
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.32M
- Employee Count
- 45
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of OnKure Therapeutics is -1.15. OnKure Therapeutics’s PEG ratio is -0.01.
- PE Ratio
- -1.15
- PS Ratio
- 0.00
- PB Ratio
- 1.01
- Price to FCF
- -2.69
- Price to Operating Cash Flow
- -3.33
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, OnKure Therapeutics had revenue of 0 and earned -59.52M in profits. Earnings per share was -4.40.
- Revenue
- 0
- Gross Profit
- -830.00K
- Operating Income
- -62.95M
- Pretax Income
- -59.52M
- Net Income
- -59.52M
- EBITDA
- -58.69M
- Earnings Per Share (EPS)
- -4.40
Cash Flow
In the last 12 months, operating cash flow was -47.89M and capital expenditures -49,000, giving a free cash flow of -47.94M billion.
- Operating Cash Flow
- -47.89M
- Free Cash Flow
- -47.94M
- Free Cash Flow per Share
- -0.96
Dividends & Yields
OnKure Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -37.34%
- Earnings Yield
- -39.08%
Stock Price Statistics
- Beta
- 1.17
- 52-Week Price Change
- -9.34%
- 50-Day Moving Average
- 2.78
- 200-Day Moving Average
- 3.62
- Relative Strength Index (RSI)
- 60.08
- Average Volume (3m)
- 297.00K
Important Dates
OnKure Therapeutics upcoming earnings date is Mar 17, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Mar 17, 2027
- Ex-Dividend Date
- ―
Financial Position
OnKure Therapeutics as a current ratio of 10.28, with Debt / Equity ratio of 0.98%
- Current Ratio
- 10.28
- Quick Ratio
- 10.28
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.00
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, OnKure Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
OnKure Therapeutics EV to EBITDA ratio is 0.37, with an EV/FCF ratio of 0.46.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.37
- EV to Free Cash Flow
- 0.46
- EV to Operating Cash Flow
- 0.47
Balance Sheet
OnKure Therapeutics has $163.31M in cash and marketable securities with $790.00K in debt, giving a net cash position of $162.51M billion.
- Cash & Marketable Securities
- $163.31M
- Total Debt
- $790.00K
- Net Cash
- $162.51M
- Net Cash Per Share
- $4.01
- Tangible Book Value Per Share
- $3.16
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for OnKure Therapeutics is $14.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $14.00
- Price Target Upside
- 388.66% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 55.14%
Scores
- Smart Score
- 3
- AI Score
- 45
